SILO

Silo Pharma ($SILO) CEO Doubles Down with More Purchases Near Lows as PTSD Treatment Advances

12/16/2025 23:38

Silo Pharma ($SILO) CEO Eric Weisblum continues his pattern of consistent stock purchases, with the latest acquisition of 5,000 shares at $0.41 per share on December 15. Including November purchases totaling 14,000 shares at $0.36-$0.41, he has invested approximately $5,582 during a period when the stock trades near yearly lows, signaling strong management confidence in the company's prospects. Silo Pharma is a micro-cap biotechnology company with a $5.4 million market capitalization, focused on developing treatments for central nervous system disorders. The company's lead pipeline candidate is SPC-15, a PTSD and anxiety treatment licensed exclusively worldwide from Columbia University. Recently, Silo partnered with Allucent to support its planned FDA Investigational New Drug (IND) application targeting 2026 submission. The CEO's purchase timing appears particularly strategic. When shares plummeted to $0.43 in May, he bought 10,000 shares, and during November's downturn to $0.36, he again stepped in with substantial purchases. His total investment since 2024 exceeds $24,000, demonstrating the pattern typically seen when insiders hold strong conviction about future value creation. The company's pipeline shows promising developments beyond SPC-15. The SP-26 ketamine implant for fibromyalgia met all primary endpoints in April's study with no implant-related adverse events reported. Additionally, Silo has expanded its intellectual property portfolio with patent applications for Alzheimer's treatments, broadening its therapeutic scope. However, the company's cryptocurrency treasury strategy introduces additional complexity. Since September, Silo has invested in Ethereum, Solana, and Bitcoin, including tokenized real-world assets on the Solana blockchain. While crypto gains could provide upside, the volatility adds another layer of risk to an already speculative investment. Key milestones investors should monitor include the 2026 IND submission for SPC-15 and early 2026 GLP-compliant toxicology study data. Positive regulatory progress could generate significant returns from current depressed levels, given the substantial market opportunity for PTSD treatments. Yet micro-cap biotech risks remain paramount. Share prices have exhibited extreme volatility, ranging from $0.36 to $3.47 over 18 months - nearly 900% variation. Clinical setbacks or funding challenges could trigger sharp declines. The company has already conducted two public offerings totaling $4.5 million this year, highlighting ongoing capital needs. The most optimistic scenario involves successful SPC-15 clinical progression combined with cryptocurrency investment gains. Conversely, clinical delays or funding shortfalls could pressure shares below current levels despite management's confidence. While CEO purchases provide encouraging signals, micro-cap biotech investments warrant strict position sizing within diversified portfolios.